CVRx, Inc. Common StockCVRX
Recorded
CVRx, Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0Duration27 min
Key takeaways
- CVRx is commercializing Barostim, the world's first autonomic neuromodulation therapy to treat heart failure.
- The device is implanted on the carotid artery and targets patients with heart failure classified as NYHA class II and III with ejection fraction less than 35% and NT-proBNP below 1600.
- The target market in the US is about $10 billion, representing approximately 5% of the heart failure population.
- Since late 2020, CVRx implemented a new go-to-market strategy focusing on a dedicated sales force, targeted account adoption, and addressing barriers of patient access, clinician awareness, and evidence.
- Significant progress has been made in reimbursement, with nearly 100% coverage for traditional Medicare patients and a new written coverage policy from Humana for Medicare Advantage patients.
- The company announced the initiation of the Benefit HF trial in March 2024, a large FDA-approved trial enrolling 2,500 patients at 150 US centers, with CMS category B reimbursement and expected duration of 3 to 5 years enrollment plus 2 years follow-up.
- CVRx ended the quarter with $65 million in cash, a $9 million burn, and access to an additional $40 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring